Ongoing and future trials of biologic therapies in lung cancer.
Lung cancer is the leading world-wide cause of cancer death. The care rate remains less than 15% despite improvements in surgery, radiotherapy and chemotherapy. The majority of deaths can be attributed to systemic metastases. Chemotherapy prolongs survival but produces few complete responses and survival at 5-years is rare. Molecular advances have provided many new targets for lung cancer therapy. Many new agents have been developed to attack these targets. This article describes current and proposed trials for these new targeted therapies in both small cell and non-small cell lung cancers.
Bunn
Paul A
PA
University of Colorado Cancer Center, Denver, CO, USA. paul.bunn@uchsc.edu
Shepherd
Frances A
FA
Sandler
Alan
A
Le Chevalier
Thierry
T
Belani
Chandra P
CP
Kosmidis
Paris A
PA
Scagliotti
Giorgio V
GV
Giaccone
Giuseppe
G
D000328:Adult; D000367:Age Factors; D000368:Aged; D020533:Angiogenesis Inhibitors / Q000494:pharmacology*; D000970:Antineoplastic Agents / Q000494:pharmacology*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018288:Carcinoma, Small Cell / Q000188:drug therapy* / Q000473:pathology; D002986:Clinical Trials as Topic; D066246:ErbB Receptors / Q000037:antagonists & inhibitors*; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011379:Prognosis; D012720:Severity of Illness Index; D016019:Survival Analysis
D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D066246:ErbB Receptors